Paul Collins is currently a Vice President and Senior Research Fellow for Bioproduct R&D at Eli Lilly and Company in Indianapolis. In his current role, Paul has responsibility for defining future technologies and development approaches for molecules associated with genetic medicine, as well as drug delivery of these entities. Paul has a long history in technology development across several areas of his company. Paul has worked in Bioproduct Development, Synthetic Technology Development, Synthetic Process Development, and Device and Drug Delivery.
During his time at Lilly, Paul has been instrumental in recruiting and developing both new and experienced engineers, as well as starting new technical capabilities necessary for Lilly’s current efforts in continuous manufacturing and peptide/siRNA production. Paul started his career with Merck and Company, working in both manufacturing and R&D. Across both companies, Paul has been involved in the process development, registration, and commercialization of six marketed pharmaceuticals. Outside of Lilly, Paul has been heavily involved with AIChE’s Pharmaceutical Division over the past decade, shaping future programming directions as well as chairing the new pharmaceutical forum in 2015 and 2016.
Paul received his BE in Chemical Engineering from Vanderbilt University in 1988 and his PhD in Biochemical Engineering from Northwestern in 1997.